Barclays PLC 89bio, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in 89bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 214,768 shares of ETNB stock, worth $1.71 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

214,768

Previous 214,768 -0.0%

Holding current value

$1.71 Million

Previous $1.59 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.36 - $9.66 $1.1 Million - $1.44 Million	149,479 Added 228.95%	214,768 $1.59 Million
Q2 2024 Aug 14, 2024	SELL	$7.31 - $10.9 $2.11 Million - $3.15 Million	-288,799 Reduced 81.56%	65,289 $523,000
Q1 2024 May 15, 2024	SELL	$8.13 - $13.77 $1.54 Million - $2.61 Million	-189,464 Reduced 34.86%	354,088 $4.12 Million
Q4 2023 Feb 15, 2024	SELL	$6.66 - $16.03 $538,214 - $1.3 Million	-80,813 Reduced 12.94%	543,552 $6.07 Million
Q3 2023 Nov 07, 2023	BUY	$15.06 - $19.41 $6.45 Million - $8.31 Million	428,297 Added 218.44%	624,365 $9.64 Million
Q2 2023 Aug 03, 2023	BUY	$14.15 - $22.03 $611,166 - $951,519	43,192 Added 28.25%	196,068 $3.72 Million
Q1 2023 May 04, 2023	SELL	$10.48 - $16.94 $2.69 Million - $4.34 Million	-256,269 Reduced 62.64%	152,876 $2.33 Million
Q4 2022 Feb 13, 2023	BUY	$5.52 - $12.73 $111,299 - $256,674	20,163 Added 5.18%	409,145 $5.21 Million
Q3 2022 Nov 03, 2022	BUY	$3.02 - $7.0 $1.1 Million - $2.55 Million	364,518 Added 1490.02%	388,982 $2.25 Million
Q2 2022 Aug 12, 2022	BUY	$2.09 - $4.02 $6,102 - $11,738	2,920 Added 13.55%	24,464 $79,000
Q1 2022 May 16, 2022	BUY	$3.45 - $14.99 $74,326 - $322,944	21,544 New	21,544 $81,000

Others Institutions Holding ETNB

# of Institutions

158

Shares Held

108M

Call Options Held

73.6K

Put Options Held

1.19M

View Full List

About 89bio, Inc.

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $369M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

More about ETNB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account